

Highly sensitive scent-detection of COVID-19 patients in vivo by trained dogs

Omar Vesga^{1,2*}, Maria Agudelo^{1,2}, Andrés F. Valencia-Jaramillo^{2,3}, Alejandro Miramontoya^{2,3}, Felipe Ossa-Ospina^{2,3,4}, Esteban Ocampo³, Karl Čiuoderis⁵, Laura Pérez⁵, Andrés Cardona⁵, Yudy Aguilar², Yuli Agudelo¹, Juan P. Hernández-Ortiz^{5,6}, Jorge E. Osorio^{5,6}.

¹ Section of Infectious Diseases, Hospital Universitario San Vicente Fundación, Medellín, Colombia.

² GRIPE, Universidad de Antioquia, Medellín, Colombia.

³ Colina K-9, La Ceja, Colombia.

⁴ Undergraduate School of Veterinary Medicine, Universidad de Antioquia, Medellín, Colombia.

⁵ Colombia/Wisconsin One-Health Consortium, Departamento de Materiales, Facultad de Minas, Universidad Nacional de Colombia, Sede Medellín, Colombia.

⁶ Department of Pathobiology, School of Veterinary Medicine, University of Wisconsin, Madison, USA.

* Corresponding author

Email: omar.vesga@udea.edu.co

32 **Abstract**

33

34 Timely and accurate diagnostics are essential to fight the COVID-19 pandemic, but no test
35 satisfies both conditions. Dogs can scent-identify the unique odors of the volatile organic
36 compounds generated during infection by interrogating specimens or, ideally, the body of a
37 patient. After training 6 dogs to detect SARS-CoV-2 in human respiratory secretions (in
38 vitro scent-detection), we retrained 5 of them to diagnose the infection by scenting the
39 patient directly (in vivo scent-detection). Then, efficacy trials were designed to compare the
40 diagnostic performance of the dogs against that of the rRT-PCR in 848 human subjects:
41 269 hospitalized patients (COVID-19 prevalence 30.1%), 259 hospital staff (prevalence
42 2.7%), and 320 government employees (prevalence 1.25%). The limit of detection in vitro
43 was lower than 10^{-12} copies ssRNA/mL. In vivo, all dogs detected 92 COVID-19 patients
44 present among the 848 study subjects. Detection was immediate, and independent of
45 prevalence, time post-exposure, or presence of symptoms, with 95.2% accuracy and high
46 sensitivity (95.9%; 95% C.I. 93.6-97.4), specificity (95.1%; 94.4-95.8), positive predictive
47 value (69.7%; 65.9-73.2), and negative predictive value (99.5%; 99.2-99.7). To determine
48 real-life performance, we waited 75 days to carry out an effectiveness assay among the
49 riders of the Metro System of Medellin, deploying the human-canine teams without
50 previous training or announcement. Three dogs (one of each breed) scent-interrogated 550
51 citizens who volunteered for simultaneous canine and rRT-PCR testing. Negative
52 predictive value remained at 99.0% (95% C.I. 98.3-99.4), but positive predictive value
53 dropped to 28.2% (95% C.I. 21.1-36.7). Canine scent-detection in vivo is a highly accurate
54 screening test for COVID-19, and it detects more than 99% of infected individuals

55 independently of the key variables. However, real-life conditions increased substantially the
56 number of false positives, indicating the necessity of training a threshold for the limit of
57 detection to discriminate environmental odoriferous contamination from infection.

58 **Introduction**

59

60 The only effective measure to ameliorate the impact of the COVID-19 pandemic is early
61 and accurate identification of people infected with SARS-CoV-2 [1]. A key aspect of any
62 pandemic is that, in order to prevent contagion, diagnostic tests must detect the pathogen in
63 asymptomatic, pre-symptomatic and symptomatic patients [2]. The reference standard is the
64 real-time reverse transcriptase-polymerase chain reaction (rRT-PCR); it is highly specific
65 (~100%), but lacks sensitivity during the first 5 days post exposure (0% on day 1, 33% on
66 day 4, 62% on day 5), and its availability is limited [3]. Lateral flow antigen tests are cheap,
67 instrument-free (easily accessible), provide results faster than rRT-PCR, and have ~100%
68 specificity as well, but sensitivity is lost 5-7 days after exposure. However, antigen tests are
69 very sensitive (84%-98%) during the pre-symptomatic period (days 1-5), complementing
70 very well the insensitive period of the rRT-PCR [4]. Antibody tests are useless to prevent
71 the dissemination of the virus, as they peak after the infectious period [5]. Several nations
72 demonstrated eloquently that massive testing to diagnose early everyone infected, followed
73 by immediate isolation in designated areas away from home, and rigorous contact-tracing,
74 were the only measures that effectively stopped the pandemic [6]. Quarantines provide time
75 to respond for health authorities, but benefit is doubtful [7], while cost is catastrophic [8].
76 Vaccines offer the solution [9], but the immunization of the world's population will take

77 years, time enough for the virus to mutate and adapt [10]. Therefore, finding strategies to
78 balance prevention with income is an emergency [11].

79

80 Humans have been using dogs - *Canis lupus familiaris* - for scent-detection since the
81 beginnings of domestication [12]. The great power of their sense of smell is exceedingly
82 useful, and the first study of their olfactory capabilities was published more than 130 years
83 ago by George J. Romanes [13], the research associate of Charles Darwin. Today, highly
84 trained dogs are invaluable not only for their service [14], but also because their accuracy is
85 definitely superior to analytical instruments [15]. Medical diagnosis by trained canines
86 triggers hope and enthusiasm among journalists [16], but it receives no attention from
87 practicing clinicians, who rely exclusively on semiology and sophisticated instruments to
88 determine what afflicts their patients [17]. The use of scent-specialized dogs to detect
89 specific conditions has been published, but most are anecdotic reports instead of formal
90 protocols designed to validate a diagnostic test for clinical use [18]. However, a few studies
91 have demonstrated that with appropriate training and strict adherence to the scientific
92 method, it is possible to obtain consistent results [19]. Recently, a comprehensive method
93 was published to validate canine diagnosis of the plant pathogens *Candidatus Liberibacter*
94 *asiaticus* [20] and *Xanthomonas citri* pv. *citri* [21], demonstrating that detection of infected
95 citrus trees by dogs was superior to quantitative PCR.

96

97 Dogs detect and differentiate unique odors that result from the emission of volatile organic
98 compounds (VOCs) that constitute the “smell print” of the target [22]. In the case of SARS-
99 CoV-2, ethyl butanoate was reported recently as the most abundant VOC in the breath of 10
100 COVID-19 patients [23]. Dogs are inherently resistant to SARS-CoV-2 [24], and even in

101 experimentally induced infections or after very close contact with an infected owner, the
102 virus cannot replicate in, cause clinical disease to, or be transmitted from canines [25].
103 After proper training of six dogs, we compared canine diagnostic performance against the
104 reference standard to determine the sensitivity (*SEN*), specificity (*SPC*), positive predictive
105 value (*PPV*), negative predictive value (*NPV*), accuracy (*ACC*), and likelihood ratio (*LR*) of
106 our dogs to detect by scent COVID-19 in vivo, i.e., by direct olfaction of the patient. The
107 product was a very fast, reliable, and cost-effective screening method for infection by
108 SARS-CoV-2 in human patients.

109

110 **Materials and Methods**

111 Detailed methodology is available in the Supporting Information file.

112 **Study Objectives**

113 Although any healthy dog can sniff and follow an odor, it cannot be forced to do it. Scent-
114 detection demands intense concentration, and it exhausts the dog mentally and physically.
115 For maximal output, working dogs must be rewarded for each positive finding with a prize
116 that conveys an extremely high value for them, and their performance depends heavily on
117 the intensity of the expectations that such reward generates in the brain of the dog during
118 training [26, 27]. Even within optimal training conditions, not all canine individuals will
119 give their best to gain a reward, and a rigorous selection process is needed before training
120 canines for delicate missions, like explosive-detectors and military working dogs [28]. For
121 instance, the Bloodhound is a working breed that excels in scent power, but it is not
122 suitable for medical detection because most individuals do not enjoy the repetitive task of
123 searching and signaling one specific odor among many human subjects [29]. Actually,

124 medical screening can be a very boring task for the dog, and most experts agree that the
125 ideal dog for scent-detection must display superlative amounts of motivation, stamina,
126 determination, and resilience [14, 15]. Animal behavior scientists avoid this
127 anthropomorphic jargon, but cognition research is providing solid evidence that dogs
128 indeed have unusual minds compared with other nonhuman animals, and that such
129 advantage comes from sharing their lives with us [30].

130

131 The principal objective of this study was to determine the performance of scent-detection
132 dogs as a screening tool in vivo for immediate detection of COVID-19 patients under a
133 variety of circumstances [31]. The design aimed at answering five research questions: One,
134 if working dogs with the above-mentioned attributes, but belonging to breeds created for
135 tasks other than olfaction, would succeed as medical detectors; a positive result would
136 increase significantly the canine population from which dogs could be selected. Two, the
137 minimal number of COVID-19 patients required to train the dogs in vitro; such number
138 must be enough for the dogs to make the inference that any human being with the same
139 smell-print is a positive. Three, the size effects of the diagnostic metrics in vitro and in vivo
140 under controlled experimental conditions, i.e., efficacy. Four, the canine limit of detection,
141 in copies of single stranded viral RNA per milliliter (ssRNA/mL). And five, the real-life
142 performance of the dogs in vivo, i.e., screening effectiveness.

143

144 **Design and sample size**

145 Screening and diagnostic tests differ in their applications, and validation of the former
146 requires a much smaller sample size [32]. In order to produce dogs capable of screening
147 humans for SARS-CoV-2 infection, teaching them to identify the virus in vitro was a

148 mandatory prerequisite. The first step was to ask written informed consent from 12 patients
149 hospitalized with COVID-19 to aliquot and ultra-freeze (-70°C) their respiratory secretions.
150 The specimens were thawed and used as needed. Demographic information of the
151 participants who provided specimens for phases 1 and 2 can be seen in Table 1. The
152 training work was planned in three phases, each followed by its corresponding
153 experimental aspect (Fig 1). Phase 1 (“in vitro recognition) lasted 28 days during which we
154 trained the dogs to recognize in vitro the scent-print of SARS-CoV-2 under a wide variety
155 of environmental modifications. One aspect of training that remained constant was the
156 error-free discrimination learning protocol developed by Terrace [33], which consists in
157 always presenting the animal a marked contrast between positive and negative stimuli [34].
158 The “stimulus” is the problem presented to the dog, which was, for in vitro diagnosis,
159 sterile saline solution (phase 1) or human saliva (phases 2), and for in vivo screening, the
160 body of a person. A stimulus can be “positive” when it leads to a reward (SARS-CoV-2), or
161 “negative”, if it does not represent a reward for the dog (controls). To recognize SARS-
162 CoV-2, we trained the dogs to find their food (the reward) using their olfaction, always
163 hiding with it a respiratory specimen from Patient 1 (the positive stimuli). The amount of
164 food was diminished progressively until only the SARS-CoV-2 specimen was left in the
165 hiding place, while the number of hides with saline increased in number. We marked the
166 correct behavior (i.e., identification of SARS-CoV-2) pressing a clicker device, and
167 immediately rewarded the dog. It took one day for all dogs to understand that finding the
168 SARS-CoV-2 specimen meant a prize for them, and that saline conveyed no reward. The
169 following 27 days of the first phase the dogs were trained with respiratory secretions from
170 Patients 1, 2 and 3 under the above-mentioned variations, but keeping constant the negative
171 stimuli (saline). The other 9 positive specimens (Patients 4-12) were reserved exclusively

172 for experimentation, which only took place after training in each of the first two phases had

173 taught the dogs the error-free skills necessary to identify SARS-CoV-2 with Patients 1-3.

174 **Table 1.** Human subjects who provided specimens for in vitro training and
175 experimentation (phases 1 and 2).


176

Patient #	Sex	Specimen	Days Sick	SARS-CoV-2 rRT-PCR	Viral Load (log ₁₀ copies ssRNA/mL)
1	Female	NPS & saliva	12	Positive	5.42
2	Male	NPS & saliva	10	Positive	ND
3	Female	NPS & saliva	5	Positive	6.90
4	Male	TA	16	Positive	5.15
5	Male	NPA	10	Positive	ND
6	Male	TA	10	Positive	5.09
7	Male	NPS	3	Positive	10.2
8	Female	Sputum	7	Positive	ND
9	Female	Sputum & saliva	5	Positive	ND
10	Female	Sputum & saliva	9	Positive	5.07
11	Male	Saliva	8	Positive	ND
12	Male	TA	13	Positive	ND
13-112	59F, 41M	Saliva	0	Negative	NA

177 NPS: nasopharyngeal swab; TA: tracheal aspirate; NPA: nasopharyngeal aspirate; F: female; M:
178 male; R: range; ND: not determined; NA: not applicable.

179

180 **Fig 1.** Efficacy studies. Flow chart depicting the order in which training phases and
181 experimental design were planned.



182 The number of days after each phase indicate the time employed training the dogs, before starting
183 the corresponding experimentation process. COVID-19 prevalence was set up as desired for in vitro
184 experiments, introducing a more difficult scenario by minimizing prevalence during phase 2 (in vitro
185 diagnosis). Prevalence during phase 3 (in vivo diagnosis) was spontaneous, given by the pandemic
186 epidemiology in our hospital, which is a large reference institution.
187
188

189 During phase 2 ("in vitro diagnosis"), we trained the dogs for 21 days keeping constant the
190 positive stimuli (specimens from Patients 1, 2 and 3), but changing the negative stimuli for
191 human saliva specimens donated by 100 human volunteers (Patients 13-112, Table 1).
192 These 100 donors were healthy, ambulatory people belonging to the general population,
193 whose saliva specimens were negative for SARS-CoV-2 by rRT-PCR the same day that we
194 aliquoted and froze them at -70°C (collection took place in March 2020, when the
195 pandemic was just starting in Colombia). To prevent replication of the microbiota within
196 each saliva sample, working specimens were thawed and kept at 4°C between uses, and

197 multiple aliquots of each specimen frozen at -70°C to replace discarded samples, granting
198 fresh samples as needed (specimens were heat-sterilized before appropriate disposal).
199 Training in phase 3 was undertaken only after experimentation demonstrated that the dogs
200 had acquired the skills provided by phase 2.

201

202 In the third phase of training (“in vivo screening”, 56 days), the dogs learned to identify
203 COVID-19 patients by scenting the human body; they always preferred the hands, then
204 search other parts of the anatomy. The rRT-PCR was the reference standard, but we also
205 included 51 seriously ill COVID-19 patients diagnosed with antigen tests and admitted to
206 the hospital with life-threatening respiratory distress. The sample sizes required (and
207 obtained) for sensitivity during experimental phases 1, 2 and 3 were 2140 (3200), 2140
208 (6000) and 310 (848), respectively; specificity requirements were much lower (Table S1)
209 [35]. The protocol was approved by the Research Ethics Committee of *Hospital*
210 *Universitario San Vicente Fundación*, and all human participants gave written informed
211 consent before enrollment.

212

213 **Dog training**


214 Using operant conditioning based on clicker-training and rewarding with food [36], six
215 canines were trained to detect the odor print of SARS-CoV-2 in saliva and in the human
216 body (Fig 2): four Belgian Shepherd Malinois (a herding breed), one first-generation cross
217 Alaskan Malamute by Siberian Husky (a Nordic sled-dog), and one pit bull (a fighting
218 breed). For every experiment, the position of the samples in the field (1 to 100) and disease
219 prevalence (1% to 10%) were randomized with a mobile phone app. For each in vitro
220 experiment, the dogs went through an open field arrangement of 10 x 10 samples (100)

221 distanced 2 m in all directions. An illustration of the experimental field and the scent-

222 detection work in vitro can be seen in Video S1.

223 **Fig 2.** Pictures and identification of the six dogs trained for the scent-detection of
224 SARS-CoV-2.

225



226 (1) Andromeda, intact female, 6-mo, Belgian Malinois (BM). (2) Nina, intact female, 25-mo, BM, (3)
227 Niño, castrated male, unknown age, American Pit Bull Terrier. (4) Timo, intact male, 31-mo, BM. (5)
228 Vika, intact female, 36-mo, BM. (6) Vita, intact female, 36-mo, first generation Alaskan Malamute x
229 Siberian Husky.

230

231 Generalization (i.e., the dog recognizes the scent-print of SARS-CoV-2 in a specimen from

232 any infected individual) in phases 1 and 2 was achieved with a small set of three COVID-

233 positive samples (Patients 1 to 3; Table 1). To demonstrate that the dogs knew that they

234 were looking for the scent-print of SARS-CoV-2 instead of the specific scents from the

235 three individuals used to train them, we used for experimentation after phases 1 and 2 the
236 specimens from Patients 4-12, to which they had never been exposed. The same principle
237 was applied to in vivo screening: we tested the dogs in patients only after obtaining very
238 high diagnostic metrics in vitro. Dogs could scent any part of the anatomy and were
239 allowed to touch with their noses the body of the patients, who were instructed to present
240 their hands opened with palms facing the dog. The relatively long time we spent in training
241 for phase 3 (56 days) had the only objective of eliminating false positives, because
242 recognition of true positives was straightforward. The dogs trained with 400 subjects who
243 did not participate in the experiments: 100 hospitalized patients (40% with COVID-19) and
244 300 health-care workers (7% with COVID-19). These training was done to improve
245 specificity and positive predictive value, because sensitivity and negative predictive value
246 never represented an obstacle. Our focus was in vivo screening, and we used in vitro
247 training and experimentation as means to arrive to our main goal, the canine detection of
248 COVID-19 by scenting the human body. To ensure that the dogs were not fixed on the
249 hospital scent, we obtained saliva samples from each of the 300 health-care workers who
250 volunteered for in vivo training, and made the dogs scent-interrogate saliva once they had
251 finished each training session in vivo: *NPV* in vitro was close to 100%, and *PPV* were
252 above 80%, indicating that they were not looking for a scent other than SARS-CoV-2.

253

254 **Dog-trainer teams biosafety: evaluation of the SARS-CoV-2** 255 **containment devices**

256 To prevent contagion of canine and human individuals participating in this study with
257 SARS-CoV-2 specimens, we contrived two devices (D1 and D2) made with the fabric of
258 the Dupont™ Tychem 2000. D1 was a used for scent-detection in saliva or respiratory

259 specimens; it was a 130-mL glass flask with a metallic lid in which we perforated a 1 cm
260 hole in the middle, and the lid allowed a hermetic closure that remained intact after placing
261 a 10x10 cm piece of Tychem 2000 between the bottle and its lid. D2 was used for the same
262 purpose but offered greater versatility than D1; it was a waterproof bag made of two 18x8
263 cm pieces of Tychem 2000, heat-sealed in its four sides after placing inside it a sterile
264 gauze impregnated with the specimen.

265

266 In order to determine if any of the dog-trainer teams got infected by, or could have been at
267 risk of exposure to SARS-CoV-2 during the project, were used two approaches: one,
268 running rRT-PCR tests in saliva of dogs and trainers by at the end of the second and third
269 phases; and two, evaluating experimentally the efficiency of our containment devices in the
270 Syrian hamster (*Mesocricetus auratus*) COVID-19 model (Fig S1). After an acclimatization
271 period of 4 weeks, we exposed during four days 15 animals of both sexes (6 females and 9
272 males) to SARS-CoV-2 in groups of 3 animals of the same sex, 2 groups for the
273 experimental arms and 3 groups as control arms, each contained in a HEPA filtered One
274 System cage. Each of the two experimental groups had inside their respective cage one of
275 the containment devices (D1 in group 1, D2 in group 2) protected by a metallic welded wire
276 mesh enclosure that allowed hamsters to smell the contraption without touching it. Each of
277 the three control groups had free access to an unprotected D1 flask (group A), a sterile
278 gauze impregnated with a fresh specimen from a different COVID-19 patient (group B), or
279 and unprotected D2 bag (group C). D1, D2 and the virus-impregnated gauze were replaced
280 with fresh SARS-CoV-2 specimens every 12 hours in the 5 groups. All hamsters were
281 sampled for rRT-PCR by saliva swabs before and after SARS-Cov-2 exposure.

282

283 **Experimentation after scent-detection training**

284 Three kinds of 2-mL specimens were prepared under a biosafety class III laminar flow
285 cabinet using 209 sterile, scent-free flasks. One-hundred flasks had 0.9% sterile saline
286 solution (phase 1, control arm), 100 had rRT-PCR-negative saliva (phase 2, control arm),
287 and 9 flasks had respiratory secretions from COVID-19 Patients 4-12 (phases 1 and 2,
288 experimental arm). The positive specimens were diluted (1:1 volume) in 0.9% sterile saline
289 solution to preserve the virus [37]. Each of the three phases of training was followed by its
290 respective experiments; phases 1 and 2 involved in vitro scent-detection of COVID-19 in
291 saliva specimens, and phase 3 concerned in vivo screening. During in vitro experiments,
292 each dog had to interrogate by scent a field with 100 flasks, the vast majority (90%-99%)
293 containing negative stimuli; the rest would have the positive stimuli. After finishing a 100-
294 flask field, the dog was offered abundant water and placed to rest in its individual kennel.
295 Before the next search, each dog was scheduled to have an unrestricted play session and to
296 take a long walk with its trainer. Once ready, the field was rearranged for a new experiment
297 changing at random the position of the specimens and the prevalence of COVID-19.

298

299 Although the majority of the experiments related to phase 1 training were unblinded, all
300 experiments for phases 2 and 3 were blinded, i.e., the dog handlers did not know the
301 position and number of positive specimens (phase 2) or patients (phase 3). Such
302 information was managed exclusively by the training director (AFVJ), whom actioned the
303 clicker immediately upon any correct indication by the canine, delivering an unequivocal
304 auditory signal that informed the human-canine team of every correct finding. This design
305 implied that the training director never interacted with the dogs during the experimental
306 process.

307

308 Immediately after ending experimentation for phase 2, we started phase 3 training at
309 *Hospital Universitario San Vicente Fundación* (HUSVF). Phase 3 experiments aimed to
310 determine the efficacy of the dogs as a COVID-19 screening tool in vivo, and included
311 inpatients from HUSVF (high-risk group), health-care workers serving at HUSVF
312 (intermediate-risk group), and employees from the office of the Governor of the
313 Department of Antioquia (low-risk group).

314

315 The effectiveness assay was executed 75 days after the last experiment of the efficacy trial,
316 and involved general population riding the Metro System of Medellin ($n = 550$, 3 dogs of 3
317 breeds). In contrast with efficacy trials, the human-canine teams were deployed to the field
318 without previous announcement or environmental training; researchers wear personal
319 protective equipment, but did not know the clinical status or particular risk factors of the
320 participants, who were informed about the test on site and recruited without further delay.
321 Since we had only three trainers, it was impossible to include more than 3 dogs in this trial.

322

323 Data input into 2x2 contingency tables generated the metrics *SEN*, *SPC*, *PPV*, *NPV* (each
324 with its 95% confidence interval), *ACC*, and *LR*. Since pooling results from experiments
325 with 100 specimens violates the independence assumption of the Fisher's exact test, we
326 performed latent class analysis for in vitro data. For in vivo data, where all assumptions
327 were rigorously checked, we applied the two-tailed Fisher's Exact Test to challenge the null
328 hypothesis that the dogs detected COVID-19 by chance.

329

330 **Limit of canine scent-detection**

331 Freshly collected saliva specimens from four COVID-19 patients (unknown to the dogs)
332 were serially diluted in sterile physiologic saline solution in 1:10 steps down to 1×10^{-12}
333 copies ssRNA/mL. The viral loads had been determined beforehand and ranged from 47 to
334 475 copies ssRNA/mL, therefore 15 dilutions were prepared for each of the four specimens.
335 Then, we randomized the dilutions from each patient by placing two COVID-19 dilutions
336 along with 8 saline controls in D1 contraptions (10 flasks per row), and commanded every
337 dog to search them until they finished the scent-interrogation of all 60 dilutions. The limit
338 of detection (LOD) was the mean of the most diluted specimens that each dog was able to
339 identify without failing a single one of the more concentrated dilutions.

340

341 **rRT-PCR assay and RNA quantification, RNA transcript 342 standard generation, assay efficiency, and analytical sensitivity**

343 The SARS-CoV-2 molecular diagnosis was conducted at the Genomic One Health
344 Laboratory, Universidad Nacional de Colombia. Details provided in Supporting
345 Information file.

346

347 **Results**

348 Detailed methodology is available in the Supporting Information file.

349

350 **Phase 1: in vitro recognition of SARS-CoV-2**

351 Once the dogs were fully proficient identifying the specimens from Patients 1, 2 and 3
352 without errors, we evaluated their performance experimentally with specimens from

353 patients to which they had not been exposed (Patients 4 to 12, Table 1). In phase 1, the
354 number of experiments varied for each dog because the required sample size (3200) was
355 reached early, all six recognized COVID-19 specimens with accuracy >95.0%, and we tried
356 to minimize the dog's exposure to the specimens from each of the 9 patients. The mean
357 prevalence of SARS-CoV-2 positive samples for these experiments was 7.56% (range,
358 5.0%-8.6%), and the effect sizes were very high for each of the six dogs (Table S2). To
359 determine if diagnostic performance would improve by increasing prevalence to 20%, we
360 set up an experiment with 40 flasks in a 10 x 4 field allocating randomly 8 positive samples
361 within 32 saline distractors. All six dogs identified correctly every sample without a single
362 mistake. With these results, dogs were ready for phase 2 training, designed for lower
363 prevalence (1%-4%) and greater difficulty to discriminate the positive from the negative
364 stimuli (saliva from 100 non-COVID subjects).

365

366 **Phase 2: in vitro diagnosis of SARS-CoV-2**

367 After phase 2 training with specimens from Patients 1-3 (positive stimuli) and 13-112
368 (negative stimuli) under a prevalence no greater than 4%, diagnostic performance was
369 determined experimentally with saliva from Patients 4-12 (experimental arm) disguised at
370 an average prevalence of 2.2% among saliva samples from healthy volunteers 13-112
371 (control arm). Compared with phase 1, there was a significant improvement in the effect
372 sizes of all metrics for every dog (Table S3). As a group, the 6 dogs achieved *SEN* 95.5%
373 (95% C.I. 90.4 - 97.9), *SPC* 99.6% (99.5 - 99.8), *PPV* 85.7% (79.2 - 90.5), *NPV* 99.9%
374 (99.8 - 100), *ACC* 99.6%, and *LR* 267. The *PPV* improved 12 percentile points, while the
375 *NPV* was close to perfection, thereby suggesting a very low probability that any of our dogs
376 would miss a positive case in vitro (Fig S2).

377

378 **Phase 3 (efficacy trial): in vivo diagnosis of SARS-CoV-2 by**
379 **direct body-scenting**

380 When the dogs interrogated the first positive patient, all six recognized the scent-print of
381 SARS-CoV-2 and went down without hesitation, identifying COVID-19. Further training
382 was needed to teach the dogs that the target odor should not be marked as positive when
383 found in fomites like beds, chairs, bedside tables, flip flops, cell phones, or other personal
384 items of the patient, but it proved to be a difficult endeavor. Contrary to false negatives,
385 always close to zero, false positives represented a serious obstacle during phase 3 training.
386 This response from the dogs proved that saliva from just 12 COVID-19 patients provided
387 enough variety for them to infer that the scent-print of the disease could be found in vivo
388 (as they had learned in vitro), and that marking patients or fomites (contaminated with the
389 target scent-print) as positive was the behavior we were asking from them. That inference
390 was our main training goal, but it was evident from day 1 that all training during phase 3
391 had to focus in reducing false positives, because the scent-print of COVID-19 was spread
392 throughout the surfaces of HUSVF, and the dogs detected it everywhere. To determine the
393 reason, we moved training to the Emergency Room (ER), which is not only the port of
394 entry for all patients, but also the busiest and most crowded service of our institution. In
395 hospitalization wards we obtained the rRT-PCR results ahead of the training session, but it
396 was impossible in the ER because patients were admitted the same day of training and
397 results came afterwards. In three independent training sessions with 50-60 patients each, we
398 found that 10% of the ER population was made of asymptomatic COVID-19 patients that
399 had passed undiagnosed after being admitted for other reasons, mostly traumatic injuries.
400 These patients were being admitted in the different surgical and medical wards,

401 contaminating all surfaces and infecting other patients, explaining the universal presence of
402 the COVID-19 scent-print. This situation forced to change our training goal to teach the
403 dogs that surfaces and fomites were not to be marked as positive, but at the cost of great
404 confusion for the dogs.

405

406 Once the training goals were achieved, we started phase 3 experimentation including 5 dogs
407 (Vika was excluded due to advanced pregnancy) and 848 human subjects belonging to
408 three groups: 269 hospitalized patients (high risk group), 259 hospital staff individuals
409 (intermediate risk group), and 320 government employees (low risk group). Experimental
410 conditions were closely controlled for the three groups, which demographics are described
411 in Table 2.

412

413 **Table 2.** Phase 3: in vivo screening, efficacy trial. Demographic and clinical
 414 characteristics of 848 participants in the scent-detection experiments.
 415

Variable		n (%)
Sex	All Participants	848 (100)
	Females	514 (60.6)
	Males	334 (39.4)
Age (years-old)	Median	56
	Mean	53
	Youngest	15
	Oldest	92
COVID-19 Prevalence	All Participants	92 of 848 (10.85)
	Government Employees	4 of 320 (1.25)
	Health-Care Workers, HUSVF	7 of 259 (2.70)
	Hospitalized Patients, HUSVF	81 of 269 (30.1)
COVID-19 Status	SARS-CoV-2 positive	92 (10.85)
	SARS-CoV-2 negative	753 (88.8)
	SARS-CoV-2 indeterminate	3 (0.35)
Result by Reference Standard	rRT-PCR positive	41 (4.83)
	rRT-PCR negative	753 (88.8)
	rRT-PCR indeterminate	3 (0.35)
	Antigen positive	51 (6.01)
	Antigen negative	0 (0)
Clinical Status at K9 Test	COVID-19, asymptomatic	18 (2.12)
	COVID-19, pre-symptomatic	0 (0)
	COVID-19, symptomatic	74 (8.73)
	Not COVID-19, but sick	188 (22.2)
	Not COVID-19, healthy	565 (66.6)
	Indeterminate, asymptomatic	2 (0.24)
	Indeterminate, symptomatic	1 (0.12)

416 HUSVF: *Hospital Universitario San Vicente Fundación*.
 417


418 Before canine scent-interrogation, we sampled the 848 participants to determine their
 419 COVID-19 status by molecular and antigen testing (Fig 3). COVID-19 was confirmed in 92
 420 patients (10.85%) and discarded in 753 (88.8%). The other 3 (0.35%) were asymptomatic
 421 subjects with “indeterminate” rRT-PCR results after repeated testing, and had to be
 422 excluded from the analysis (Fig 4). The average cycle threshold (C_T) of the rRT-PCR
 423 positive patients was 32.0 (range, 20.6-38.8). COVID-19 was diagnosed by antigen test
 424 (Standard Q COVID-19 Ag Test, SD Biosensor) in 51 patients that had been admitted to the

425 ER with acute respiratory distress, fever, sinus pain, cough, anosmia, or dysgeusia. Out of
426 753 COVID-19 negative patients, 188 were hospitalized for other diseases that included
427 respiratory conditions (23%, half had bacterial infections), malignancy (19%),
428 autoimmunity (8%), coronary or peripheral atherosclerosis (7%), diabetes mellitus (6%), or
429 chronic osteomyelitis (6%), and the rest had traumatic injuries, peritonitis, HIV, or
430 cholangitis, among other pathologies. Of note, the dogs did not mark as positive any of the
431 patients with respiratory diseases other than COVID-19. The prevalence of COVID-19 was
432 10.85% for the study population (92 of 848 subjects), distributed this way based on pre-test
433 risk: 30.1% (81 of 269), 2.70% (7 of 259), and 1.25% (4 of 320) for the high, intermediate,
434 and low-risk groups, respectively. As a group, the five dogs achieved *SEN* 95.9% (95% CI
435 93.6 - 97.4), *SPC* 95.1% (94.4 - 95.8), *PPV* 69.7% (65.9 - 73.2), *NPV* 99.5% (99.2 - 99.7),
436 *ACC* 95.2%, and *LR* 19.6 (Table 3). Individual performance mirrored closely the group
437 metrics (Fig 5). Four of 320 participants in the low-risk group had positive rRT-PCR tests
438 (prevalence 1.25%), but none did show up for the canine scent test. It produced zero values
439 in two cells of the 2x2 contingency tables, preventing the computation of size effects (Fig
440 4).

441

442

443 **Fig 3.** Efficacy trial: diagram illustrating the flow of human participants in the third
 444 phase of the study (in vivo screening).
 445



446
 447
 448

449 **Fig 4.** Efficacy trial: data analysis by risk group of all participants in experiments
 450 designed to determine performance metrics of the dogs during in vivo screening.
 451

848 subjects tested for COVID-19														
High Risk: 269 HUSVF Inpatients				Intermediate Risk: 259 HUSVF HCWs				Low Risk: 320 employees Governor of Antioquia						
COVID-19 PREVALENCE: 10.8% of 848														
30.1%				2.70%				1.25%						
COVID-19 Test Result (rRT-PCR)														
(+) (-) INDET. Effect Size (95% C.I.)				(+) (-) INDET. Effect Size (95% C.I.)				(+) (-) INDET. Effect Size (95% C.I.)						
81 186 2				7 252 0				4 315 1						
K9 DIAGNOSIS	ANDROMEDA	POSITIVE →	81	1	1	SEN=1 (0.9547-1.0)	5	6	0	SEN=0.7143 (0.3589-0.9492)	0	39	1	NAN
		NEGATIVE →	0	185	1	SPC=0.9946 (0.9702-0.9997)	2	246	0	SPC=0.9762 (0.9490-0.9890)	0	269	0	SPC=0.8734 (0.8316-0.9060)
		Refused to Scent Subject →	0	0	0	PPV=0.9878 (0.9341-0.9994)	0	0	0	PPV=0.4545 (0.2127-0.7199)	0	7	0	PPV=0 (0.0-0.0897)
	NINA	POSITIVE →	80	6	1	SEN=0.9877 (0.9333-0.9994)	1	8	0	SEN=0.1429 (0.0073-0.5131)	0	24	1	NAN
		NEGATIVE →	1	180	1	SPC=0.9677 (0.9314-0.9851)	6	244	0	SPC=0.9683 (0.9386-0.9838)	0	284	0	SPC=0.9221 (0.8867-0.9471)
		Refused to Scent Subject →	0	0	0	PPV=0.9302 (0.8560-0.9676)	0	0	0	PPV=0.1111 (0.0057-0.4350)	0	7	0	PPV=0 (0.0-0.1380)
NIÑO	POSITIVE →	79	4	1	SEN=1 (0.9536-1.0)	5	4	0	SEN=0.7143 (0.3589-0.9492)	0	19	0	NAN	
	NEGATIVE →	0	182	1	SPC=0.9785 (0.9460-0.9916)	2	248	0	SPC=0.9841 (0.9599-0.9938)	0	294	1	SPC=0.9393 (0.9071-0.9608)	
	Refused to Scent Subject →	2	0	0	PPV=0.9518 (0.8825-0.9811)	0	0	0	PPV=0.5556 (0.2667-0.8112)	0	2	0	PPV=0 (0.0-0.1682)	
TIMO	POSITIVE →	81	25	1	SEN=1 (0.9547-1.0)	5	6	0	SEN=0.7143 (0.3589-0.9492)	0	15	1	NAN	
	NEGATIVE →	0	159	1	SPC=0.8641 (0.8071-0.9062)	2	246	0	SPC=0.9762 (0.9490-0.9890)	0	308	0	SPC=0.9524 (0.9229-0.9709)	
	Refused to Scent Subject →	0	2	0	PPV=0.7642 (0.6750-0.8348)	0	0	0	PPV=0.4545 (0.2127-0.7199)	0	0	0	PPV=0 (0.0-0.2039)	
VITA	POSITIVE →	77	3	1	SEN=0.9506 (0.8798-0.9806)	6	2	0	SEN=0.8571 (0.4869-0.9927)	0	22	0	NAN	
	NEGATIVE →	4	183	1	SPC=0.9839 (0.9537-0.9956)	1	250	0	SPC=0.9921 (0.9715-0.9986)	0	293	1	SPC=0.9302 (0.8965-0.9534)	
	Refused to Scent Subject →	0	0	0	PPV=0.9625 (0.8955-0.9898)	0	0	0	PPV=0.7500 (0.4093-0.9556)	0	0	0	PPV=0 (0.0-0.1487)	
SK9	POSITIVE →	398	39	5	SEN=0.9876 (0.9713-0.9947)	22	26	0	SEN=0.6286 (0.4634-0.7683)	0	119	3	NAN	
	NEGATIVE →	5	889	5	SPC=0.9580 (0.9341-0.9691)	13	1234	0	SPC=0.9794 (0.9699-0.9859)	0	1440	2	SPC=0.9237 (0.9094-0.9358)	
	Refused to Scent Subject →	2	2	0	PPV=0.9108 (0.8803-0.9340)	0	0	0	PPV=0.4583 (0.3258-0.5971)	0	16	0	PPV=0 (0.0-0.0313)	

452
 453 Green, yellow, orange and purple cells contain true positives, false positives, false negatives, and
 454 true negatives, respectively. Cells not enhanced contain the number of participants with
 455 "indeterminate" rRT-PCR (3), subjects who declined K9 olfaction (4), and those rare occasions
 456 where the dogs refused to scent an individual, which happened 7 times with Andromeda and Nina
 457 and 2 times with Niño. Sensitivity could not be computed in the low risk group (NAN: not a number)
 458 because all 4 COVID-19 patients declined K9 scent-detection, resulting in 0 in two cells of the 2x2
 459 contingency table and not significant P values in the two-tailed Fisher's Exact Test (enhanced in
 460 salmon color).

461
 462


463 **Table 3. In vivo screening (efficacy trial).** Performance metrics of five dogs after 13 weeks of
 464 scent-detection training. Dogs scent-interrogated 848 subjects that included 269 hospitalized patients, 259
 465 health-care workers from the same institution, and 320 government employees; n varies slightly between dogs
 466 because a participant did not show up for the dog test or the dog refused to interrogate an individual. Dog
 467 trainers were blinded regarding the COVID-19 status of all subjects. *P* values (Fisher’s Exact Test) express
 468 the probability that the dogs identified the patients infected by SARS-CoV-2 by chance alone.
 469

Metric	Dog Name (breed) and Effect Sizes [95% Confidence Intervals]					
	Andromeda (BM)	Nina (BM)	Niño (PB)	Timo (BM)	Vita (AMxSH)	All 5 Dogs
Prevalence (%)	10.6	10.6	10.3	10.5	10.5	10.5
n	834	834	836	839	841	4184
TP	86	81	84	86	83	420
TN	700	708	724	705	726	3563
FP	46	38	26	46	27	183
FN	2	7	2	2	5	18
SEN (%)	97.7 [92.1-99.6]	92.1 [92.1-99.6]	97.7 [91.9-99.6]	97.3 [92.1-99.6]	94.3 [87.4-97.6]	95.9 [93.6-97.4]
SPC (%)	93.8 [91.9-95.4]	94.9 [91.9-95.4]	96.5 [95.0-97.6]	93.9 [91.9-95.4]	96.4 [94.8-97.5]	95.1 [94.4-95.8]
PPV (%)	65.2 [56.7-72.8]	68.1 [56.7-72.8]	76.4 [67.6-83.3]	65.2 [56.7-72.8]	75.5 [66.6-82.6]	69.7 [65.9-73.2]
NPV (%)	99.7 [99.0-100]	99 [99.0-100]	99.7 [99.0-100]	99.7 [99.0-100]	99.3 [98.4-99.7]	99.5 [99.2-99.7]
ACC (%)	94.2	94.6	96.7	94.3	96.2	95.2
LR	15.9	18.1	28.2	16.0	26.3	19.6
P	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001

470 TP: true positives; TN: true negatives; FP: false positives; FN: false negatives; BM: Belgian
 471 malinois; PB: Pit bull; AMxSH: Alaskan malamute by Siberian husky first generation cross.

472
 473

474 **Fig 5. In vivo screening (efficacy trial).** Prevalence, 10.5%. Each symbol has a different color to
475 ease visualization of the dogs. The vertical lines above and below the symbols represent the 95% confidence
476 interval for each metric, which is contained within the symbol for *SPC*, *NPV* and *ACC*.
477



478

479

480 **Effectiveness assay: in vivo screening of citizens riding the** 481 **Metro System of Medellin**

482 The mass transit service of Medellin transports 1.5 million passengers every day. Without
483 prior notification to the San Antonio station users or the dog-trainer teams, three canines
484 screened over two days 550 individuals who also volunteered to provide saliva specimens
485 for rRT-PCR testing. Despite the environmental impact on the concentration of the dogs,
486 they detected 17 COVID-19 cases with high *SPC* and *NPV*. During the first hours of the
487 assay, effect sizes for *SEN* and *PPV* dropped significantly in comparison with the efficacy
488 trial (Table 4, Fig 6), but the dogs adjusted within hours to the new environment and
489 improved their performance until reaching a plateau (Fig 7).


490

491 **Table 4. Effectiveness assay to determine dog performance during in vivo**
 492 **screening under real-life conditions.** Performance metrics of three dogs in the Metro System of
 493 Medellin. Without new training or environmental habituation, dogs scent-interrogated 550 volunteers
 494 recruited on site. Simultaneous rRT-PCR in saliva led to detection of 17 COVID-19 patients, all
 495 asymptomatic or mildly symptomatic. Obviously, the research team was blinded regarding the diagnosis of all
 496 subjects. *P* values (Fisher’s Exact Test) express the probability that the dogs identified the patients infected by
 497 SARS-CoV-2 by chance alone.
 498

Metric	Dog Name (breed) and Effect Sizes [95% Confidence Intervals]							
	Andromeda (BM)		Niño (PB)		Vita (AMxSH)		All 3 Dogs	
	Effect Size	95% C.I.	Effect Size	95% C.I.	Effect Size	95% C.I.	Effect Size	95% C.I.
Prevalence (%)	3.1		3.1		3.1		3.1	
n	550		550		550		1650	
TP	15		6		14		35	
TN	483		521		506		1510	
FP	50		12		27		89	
FN	2		11		3		16	
<i>SEN (%)</i>	88.24	65.7 to 97.9	35.3	17.3 to 58.7	82.4	59.0 to 93.8	68.6	55.0 to 79.7
<i>SPC (%)</i>	90.62	87.9 to 92.8	97.7	96.1 to 98.7	94.9	92.7 to 96.5	94.4	93.2 to 95.5
<i>PPV (%)</i>	23.08	14.5 to 34.6	33.3	16.3 to 56.3	34.1	21.6 to 49.5	28.2	21.1 to 36.7
<i>NPV (%)</i>	99.59	98.5 to 99.9	97.9	96.3 to 98.8	99.4	98.3 to 99.8	99.0	98.3 to 99.4
<i>ACC (%)</i>	90.6		95.8		94.5		93.6	
<i>LR</i>	9.41		15.7		16.3		12.3	
<i>P</i>	<0.0001		<0.0001		<0.0001		<0.0001	

499 TP: true positives; TN: true negatives; FP: false positives; FN: false negatives; BM: Belgian
 500 malinois; PB: Pit bull; AMxSH: Alaskan malamute by Siberian husky first generation cross.
 501
 502

503 **Fig 6.** In vivo screening (effectiveness assay). Performance metrics of three dogs
504 in the Metro System of Medellin; prevalence, 3.1%. Each symbol has a different color to ease
505 visualization of the dogs. The vertical lines above and below the symbols represent the 95% confidence
506 interval for each metric, which is contained within the symbol for *NPV* and *ACC*.
507




508
509

510

511 **Fig 7. In vivo screening (effectiveness assay). Canine adjustment to a real-life**
512 **situation.** Accuracy started much lower under real-life conditions, but improved with time
513 as the dogs adjusted to the new environment. Numbers labeling the abscissa represent the
514 order in which subjects were screened by the dogs, divided in groups of 110 individuals.
515 Scent-interrogation of each group took approximately one hour of work for the dogs.

516



517

518

519 **Limit of canine scent-detection**

520 The LOD was determined in vitro using freshly collected saliva specimens from four
521 COVID-19 patients new to the dogs. The moment of this assay coincided with the estrus
522 cycle of several females, which caused the exclusion of the males from this experiment
523 because both refused to work. The LOD for Andromeda, Nina, Vika, and Vita was lower
524 than 2.61×10^{-12} copies ssRNA/mL (Table S4), the equivalent of detecting a drop (0.05
525 mL) of any odorous substance dissolved in a volume of water greater than the capacity of
526 10.5 Olympic swimming pools (2.6×10^{10} mL).


527

528 **Biosafety of the canine and human team handling the virus**
529 None of the dogs, their trainers, or the physician-scientists in charge of sampling and taking
530 care of the patients contracted COVID-19 during this study. The rRT-PCR tests for SARS-
531 CoV-2 from canines and humans resulted negative twice, once after ending the in vitro
532 phase, and again after finishing the in vivo phase of the study (Table S5). Experimental
533 testing of the contraptions to contain SARS-CoV-2 showed that both devices worked as
534 intended, allowing the scent to evaporate while holding the virus secured inside (Fig 8).
535 Test hamsters climbed and smelled the mesh-protected contraptions D1 (group 1) and D2
536 (group 2), but no animal contracted SARS-CoV-2. Control hamsters group A did climb on
537 D1 but could not damage the Tychem 2000 fabric covering the flask, and none got infected;
538 group C did bite the Tychem of D2, and 1 animal was infected; and group B played, bit,
539 nested, and slept in the gauze impregnated with SARS-CoV-2, and the three hamsters in the
540 cage acquired SARS-CoV-2 (Table S6).

541

542

543 **Fig 8. Biosafety data. Experimental evaluation of the contraptions devised to**
544 **contain SARS-CoV-2.** After testing negative for SARS-CoV-2 in saliva, 5 groups of 3 golden Syrian
545 hamsters each were exposed during 4 days to SARS-CoV-2 directly (Group B, virus control) or enclosed in
546 devices 1 (D1) and 2 (D2). Animals in test groups 1 (D1) and 2 (D2) were allowed to smell their devices but
547 could not touch them, while the hamsters allocated to control groups A (D1) and C (D2) had direct access to
548 the containment fabric. The ordinate represents the viral load in saliva of each hamster after exposure to
549 SARS-CoV-2 in 5 experimental groups.
550



551
552

553 Discussion

554 This study shows that canine scent-detection of COVID-19 is immediate, accurate,
555 applicable anytime, and deployable anywhere as a diagnostic test in saliva or respiratory
556 secretions, or as a screening tool in the patient directly. In any of those two roles, the dogs
557 missed very few infected individuals, as demonstrated by $NPV > 99\%$ in vitro and in vivo,
558 and independently of the experimental design (in vivo efficacy and effectiveness trials).
559 COVID-19 severity, ranging from asymptomatic to pre-symptomatic, sick and very sick
560 patients, had no impact on performance. Prevalence from three populations of diverse
561 levels of risk showed, as expected, that PPV went down when the presence of the disease in

562 the population is very low, but *NPV* remained close to 100% across low and high
563 prevalence. The error-free training system prepared the dogs for in vitro diagnosis in
564 improvised, open fields, making sophisticated and expensive equipment superfluous.
565
566 In vivo screening generated very encouraging results in both, efficacy and effectiveness
567 trials: the dogs detected more than 99% of the infected individuals spending <5 seconds per
568 subject. Such output is ideal, because it allows immediate identification and isolation of all
569 contagious subjects. However, the effectiveness assay also demonstrated that, under real-
570 life conditions, odor contamination causes a substantial increment in the false positive rate
571 driving down the *PPV*: only 28 of 100 dog-positive subjects would have simultaneously a
572 positive rRT-PCR result; the other 72 would be rRT-PCR negative. It means that for each
573 true positive, the dogs produce 2.5 false positives, an acceptable error rate for any screening
574 test offering a very high *NPV* [38, 39]. The ultra-sensitive limit of detection ($<10^{-12}$ copies
575 ssRNA/mL) suggests that at least a fraction of the “false positives” are actually pre-
576 symptomatic COVID-19 patients: during training, the dogs marked as positive three nurses
577 which rRT-PCR was negative, but the three of them had symptomatic COVID-19
578 demonstrated 4-7 days later. We also observed several times during training that the dogs
579 spontaneously marked as positive the scientists that had touched any COVID-19 patient, or
580 the cell phones of nurses and physicians in care of COVID-19 patients. It means that
581 trained canines detect the scent-print of SARS-CoV-2 in contaminated individuals or in
582 their belongings and, since contamination could lead to infection [40], the dogs actually
583 identify potential COVID-19 cases before infection takes place. Although such capacity
584 would result quite useful to follow-up contacts, it caused the high rate of false positives in
585 the effectiveness assay. Inasmuch as the index test (rRT-PCR) is not very sensitive in the

586 pre-symptomatic stage [3, 41], it is possible that some of the dog's false positives actually
587 represent true positives, a scenario where the canine test exceeds the gold standard.
588 However, this trial was not designed to test such hypothesis.

589

590 The data provided the answer for the other three research questions. First, the limit of
591 detection in vitro was lower than 2.61×10^{-12} copies ssRNA/mL, close to previous
592 concentration thresholds determined with pure chemicals [42]. Second, all six dogs
593 succeeded as medical detectors despite that their breeds are not intended for that purpose. It
594 supports recent data showing that canines, independently of breed, could serve as a medical
595 detection dogs if they exhibit motivation, stamina, determination, and resilience [43, 44].
596 And third, only three COVID-19 patients sufficed for our dogs to recognize the scent-print
597 of this particular disease in fresh saliva specimens, as demonstrated before with wildlife
598 detection dogs [45]. With that knowledge, the dogs made the generalization necessary to
599 diagnose COVID-19 in saliva of other nine patients disguised among saliva from 100
600 negative controls. And that generalization was all they needed to make the inference that
601 the same odor, emanating from a human being, implied to lay down, the behavior trained to
602 indicate that such individual was positive for COVID-19.

603

604 Some experts believe that training with positive stimulus from a few COVID-19 patients
605 (just three in this case) could lead the dog to learn by memory the scent-print of the
606 individuals instead of that of the virus, and that "at least a hundred" positive donors are
607 needed [46]. We found that such belief is unfounded: on the one hand, our dogs identified
608 the positive specimens of 9 unknown patients in phase 2, and almost all 105 patients
609 infected by SARS-CoV-2 in phase 3. On the other hand, research on the concept of

610 working memory demonstrated that expert detection dogs remembered a new scent-print
611 98% of the time as long as it was located first in a line-up with five distractors, but
612 performance went down when the positive stimulus was located farther, dropping to 11.5%
613 at the sixth location [29]. Therefore, it seems impossible for a dog to remember the odor of
614 up to 12 different individuals randomly allocated among 100 distractors. These data suggest
615 that dogs are not relying in memory when they detect SARS-CoV-2 and discriminate it
616 among so many other odoriferous cues. In fact, dogs are capable not only of generalization
617 [47], they do make inferences [48]. Furthermore, dogs have the capacity, without previous
618 training, to categorize new objects based on their functionality instead of on their
619 perceptual similarity [49]. Not long ago, cognitive skills like making inferences and
620 categorization, or the understanding of the meaning of words [50], were considered
621 exclusive of *Homo sapiens*, but studies with dogs exposed to new toys a single time and
622 only during one minute clearly showed that we have been underestimating the cognition
623 capacity of canines as study subjects [51]. These reductionist preconceptions also explain
624 the lack of interest displayed by the medical and scientific communities, as well as the
625 funding agencies, in this approach to the diagnosis of infectious diseases [52].

626

627 Although nasopharyngeal swabs were first established as the method of choice to take the
628 specimens for rRT-PCR for SARS-CoV-2, we used saliva because there is solid evidence
629 demonstrating that it is more sensitive than nasopharyngeal swabs [53], sampling is faster
630 and much easier, the need for sterile swabs is eliminated as well as the uncomfortable
631 introduction of a foreign object through the nose of the patient and, contrary to the
632 nasopharynx, the viral loads in saliva predict severity [54]. Also, we refrained from using
633 saliva from non-COVID hospitalized patients as negative stimuli to adhere to error-free

634 discrimination learning [33, 34]. The microbiological environment of hospitals is
635 dominated by human pathogens, while healthy people is inhabited by myriads of functional
636 commensals that play an irreplaceable role in physiology [55]. Soon after admission,
637 nosocomial pathogens starts replacing the microbiota of the inpatients [56], and COVID-19
638 victims are not an exception [57]. Therefore, negative stimuli (saliva) from hospitalized
639 patients would provide much less contrast with the positive stimuli than saliva from healthy
640 people, increasing the probability of error during training.

641

642 This study has some limitation that deserve attention. First, there are no human coronavirus
643 strains involved, therefore it is impossible to predict if the dogs can discriminate them from
644 SARS-CoV-2 or, even less, from other non-human coronavirus. Since human coronavirus
645 usually cause mild upper respiratory infections, these patients rarely need hospitalization
646 and were not part of our sample. We did find that none of the 43 hospitalized patients with
647 respiratory conditions other than COVID-19 was positive for the dogs despite the fact that
648 half of them had pneumonia caused by bacterial or viral pathogens like influenza virus.
649 Second, the dogs did not have the opportunity to scent-interrogate any of the four COVID-
650 19 subjects from the low-risk group because they relinquished that part of the study. This
651 prevented statistical calculations necessary to determine the size effects of the different
652 performance metrics under very low prevalence (1.25%). The third limitation arose during
653 dog training, and it caused the sharp decline in *PPV* from 69.7% to 28.2% between efficacy
654 and effectiveness trials. To improve *PPV*, it is necessary to teach the dogs that there is a
655 cut-off value in odor intensity below which they should disregard the COVID-19 scent-
656 print. However, more research is needed to identify such threshold value and to know if it

657 is worth to train for that, because it might be an asset to have dogs that can detect the virus
658 immediately after a patient gets contaminated with it.

659

660 After our preprint [58], at least four studies on canine scent-detection of SARS-CoV-2 in
661 vitro have been formally published [59-63], and despite substantial methodological
662 differences with our work, results are reproducible. The main difference with those studies
663 is that we chose to scent-interrogate the human body instead of a specimen, and did it
664 because of the many obvious advantages that such approach brings: results are immediate,
665 can be obtained anywhere, do not require equipment, and allow in situ separation of
666 contagious individuals. The use of trained dogs as medical detectors was safe for the human
667 participants during training and experimentation regardless of the breed, a point of major
668 importance considering that deployment would require the participation of many canines
669 [64, 65], and the possibility of training dogs for real-time diagnosis of many other
670 infectious diseases may help humanity be better prepared to confront the next pandemic
671 [66]. These data suggest that well-trained dogs may aid the safe re-opening of economies
672 and educational systems, while offering an efficient way to control the pandemic.

673

674 **Acknowledgments**

675 We thank sincerely the patients and staff of HUSVF and the officers of the Governor of
676 Antioquia for participating in the study.

677

678 **References**

- 679 1. Botti-Lodovico Y, Rosenberg E, Sabeti PC. Testing in a Pandemic - Improving Access,
680 Coordination, and Prioritization. *N Engl J Med.* 2021; 384:197-199.
- 681 2. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles' heel of
682 current strategies to control Covid-19. *N Engl J Med.* 2020; 382:2158-2160.
- 683 3. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative
684 rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by
685 time since exposure. *Ann Intern Med.* 2020; 173:262-267.
- 686 4. Centers for Disease Control and Prevention. Interim guidelines for rapid antigen testing
687 for SARS-CoV-2. [https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html)
688 [tests-guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html).
- 689 5. Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody
690 testing. [https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html)
691 [guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html).
- 692 6. EndCoronavirus. Countries beating COVID-19. Available at:
693 <https://www.endcoronavirus.org/countries>
- 694 7. Allen DW. Covid Lockdown Cost/Benefits: A Critical Assessment of the Literature.
695 April 2021. Available at: <http://www.sfu.ca/~allen/LockdownReport.pdf>.
- 696 8. Yu KDS, Aviso KB, Santos JR, Tan RR. The Economic Impact of Lockdowns: A
697 Persistent Inoperability Input-Output Approach. *Economies.* 2020; 8:109. doi:
698 10.3390/economies8040109.
- 699 9. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA
700 Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med.* 2021;
701 384:1412-1423.

- 702 10. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-
703 CoV-2 variants B.1.351 and B.1.1.7. *Nature*. 2021 Mar 8. doi: 10.1038/s41586-021-
704 03398-2.
- 705 11. Barnes M, Sax PE. Challenges of “return to work” in an ongoing pandemic. *N Engl J*
706 *Med*. 2020; 383:779-786.
- 707 12. Shipman, P. *The invaders: how humans and their dogs drove Neanderthals to*
708 *extinction*. Cambridge: The Belknap Press; 2015.
- 709 13. Romanes GJ. Experiments on the sense of smell in dogs. *Nature*. 1887; 36:273–274.
- 710 14. Jezierski T, Ensminger J, Papet LE, editors. *Canine olfaction science and law: advances*
711 *in forensic science, medicine, conservation, and environmental remediation*. New York:
712 CRC Press; 2016.
- 713 15. Helton WS. *Canine ergonomics: the science of working dogs*. New York: CRC Press;
714 2009.
- 715 16. Goodavage M. *Doctor dogs: how our best friends are becoming our best medicine*. New
716 York: Penguin Random House LLC; 2019.
- 717 17. Bijland LR, Bomers MK, Smulders YM. Smelling the diagnosis. A review on the use of
718 scent in diagnosing disease. *Neth J Med*. 2013; 71:300-307.
- 719 18. Cambau E, Poljak M. Sniffing animals as a diagnostic tool in infectious diseases. *Clin*
720 *Microbiol Infect*. 2020; 26:431-435.
- 721 19. Bomers MK, van Agtmael MA, Luik H, Vandenbroucke-Grauls CMJE, Smulders YM.
722 A detection dog to identify patients with *Clostridium difficile* infection during a hospital
723 outbreak. *J Infect*. 2014; 69:456-461.

- 724 20. Gottwald T, Poole G, McCollum T, Hall D, Hartung J, Bai J, et al. Canine olfactory
725 detection of a vectored phyto-bacterial pathogen, *Liberibacter asiaticus*, and integration
726 with disease control. *Proc Natl Acad Sci.* 2020; 117:3492-3501.
- 727 21. Gottwald T, Poole G, Taylor E, Luo W, Posny D, Adkins S, et al. Canine olfactory
728 detection of a non-systemic phyto-bacterial citrus pathogen of international quarantine
729 significance. *Entropy (Basel).* 2020; 22:1269. doi: 10.3390/e22111269.
- 730 22. Angle C, Angle C, Waggoner LP, Ferrando A, Haney P, Passler T. Canine detection of
731 the volatilome: a review of implications for pathogen and disease detection. *Front Vet*
732 *Sci.* 2016; 3:47.
- 733 23. Chen H, Qi X, Ma J, Zhang C, Feng H, Yao M. Breath-borne VOC Biomarkers for
734 COVID-19. *MedRxiv [Preprint].* 2020 medRxiv 2020.06.21.20136523 [posted 2020
735 June 24; cited 2021 Apr 17]: [11 p]. Available from:
736 <https://doi.org/10.1101/2020.06.21.20136523>.
- 737 24. Damas J, Hughes GM, Keough KC, Painter CA, Persky NS, Corbo M, et al. Broad host
738 range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in
739 vertebrates. *Proc Natl Acad Sci.* 2020; 117:22311-22322.
- 740 25. Bosco-Lauth AM, Hartwig AE, Porter SM, Gordy PW, Nehring M, Byas AD, et al.
741 Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis,
742 transmission, and response to reexposure in cats. *Proc Natl Acad Sci.* 2020; 117:26382-
743 26388.
- 744 26. Thorndike EL. *Animal Intelligence: Experimental Studies.* New York: The McMillan
745 Company; 1911.

- 746 27. Porritt F, Shapiro M, Waggoner P, Mitchell E, Thomson T, Nicklin S, et al.
747 Performance decline by search dogs in repetitive tasks, and mitigation strategies. Appl
748 Anim Behav Sci. 2015; 166:112-122.
- 749 28. Cobb M, Branson N, McGreevy P, Lill A, Bennett P. The advent of canine performance
750 science: offering a sustainable future for working dogs. Behav Process. 2015; 110:96-
751 104.
- 752 29. Gadbois S, Reeve C. Canine olfaction: scent, sign, and situation. In: Horowitz A, editor.
753 Domestic dog cognition and behavior: the scientific study of *Canis familiaris*. Berlin:
754 Springer-Verlag; 2014. pp. 2-30.
- 755 30. Hare B, Ferrans M. Is cognition the secret to working dog success? Anim Cogn. 2021
756 Mar 9. doi: 10.1007/s10071-021-01491-7.
- 757 31. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD
758 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ
759 (Clinical research ed.). 2015; 351:h5527. doi:10.1136/bmj.h5527.
- 760 32. Bujang MA, Adnan TH. Requirements for minimum sample size for sensitivity and
761 specificity analysis. J Clin Diagn Res. 2016; 10:YE01-YE06. doi:
762 10.7860/JCDR/2016/18129.8744
- 763 33. Terrace HS. Discrimination learning with and without “errors”. J Exp Anal Behav.
764 1963; 6:1–27.
- 765 34. Terrace HS. Wavelength generalization after discrimination learning with and without
766 errors. Science. 1964; 144:78-80.
- 767 35. Cohen J. Statistical power analysis for the behavioral sciences. Mahwah, NJ: Lawrence
768 Erlbaum Associates; 1988.
- 769 36. Spector M. Clicker Training for Obedience. Waltham, MA: Sunshine Books; 2005.

- 770 37. Radbel J, Jagpal S, Roy J, Brooks A, Tischfield J, Sheldon M, et al. Detection of Severe
771 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is comparable in clinical
772 samples preserved in saline or viral transport medium. *J Mol Diagn.* 2020; 22:871-875.
773 doi: 10.1016/j.jmoldx.2020.04.209.
- 774 38. National Academies of Sciences, Engineering, and Medicine 2020. Rapid Expert
775 Consultation on Critical Issues in Diagnostic Testing for the COVID-19 Pandemic
776 (November 9, 2020). Washington, DC: The National Academies Press.
777 <https://doi.org/10.17226/25984>.
- 778 39. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 test sensitivity - A strategy
779 for containment. *N Engl J Med.* 2020 Nov 26;383(22):e120. doi:
780 10.1056/NEJMp2025631.
- 781 40. Behzadinasab S, Chin AWH, Hossein M, Poon LLM, Ducker WA. SARS-CoV-2 virus
782 transfers to skin through contact with contaminated solids. *MedRxiv [Preprint].* 2021
783 medRxiv 2021.04.24.21256044 [posted 2021 April 28; cited 2021 May 2]: [18 p].
784 Available from: <https://doi.org/10.1101/2021.04.24.21256044>.
- 785 41. Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection -
786 challenges and implications. *N Engl J Med.* 2020. doi:10.1056/NEJMp2015897.
- 787 42. Walker DB, Walker JC, Cavnar PJ, Taylor JL, Pickel DH, Hall SB, et al. Naturalistic
788 quantification of canine olfactory sensitivity. *Appl Anim Behav Sci.* 2006; 97:241–254.
- 789 43. Turcsán B, Kubinyi E, Miklósi A. Trainability and boldness traits differ between dog
790 breed clusters based on conventional breed categories and genetic relatedness. *Appl*
791 *Anim Behav Sci.* 2011; 132:61–70. doi: 10.1016/j.applanim.2011.03.006.

- 792 44. Leighton EA, Hare E, Thomas S, Waggoner LP, Otto CM. A solution for the shortage
793 of detection dogs: a detector dog center of excellence and a cooperative breeding
794 program. *Front Vet Sci.* 2018; 5:284. doi: 10.3389/fvets.2018.00284.
- 795 45. Oldenburg Jr C, Schoon A, Heitkönig IMA. Wildlife detection dog training: A case
796 study on achieving generalization between target odor variations while retaining
797 specificity. *J Vet Behav.* 2016; 13: 34e38. doi: 10.1016/j.jveb.2016.03.008
- 798 46. WHO R&D Blueprint [Internet]: Geneva, Switzerland: COVID-19 Consultation on the
799 use of trained dogs for screening COVID-19 cases. 8th March 2021 [cited 2021 Apr
800 14]. Available from: [https://cdn.who.int/media/docs/default-source/blue-print/who-](https://cdn.who.int/media/docs/default-source/blue-print/who-consultation-screening-dogs--8th-march-2021.pdf?sfvrsn=a0d8cbda_1&download=true)
801 [consultation-screening-dogs--8th-march-2021.pdf?sfvrsn=a0d8cbda_1&download=true](https://cdn.who.int/media/docs/default-source/blue-print/who-consultation-screening-dogs--8th-march-2021.pdf?sfvrsn=a0d8cbda_1&download=true)
- 802 47. Moser AY, Bizo L, Brown WY. Olfactory generalization in detector dogs. *Animals.*
803 2019; 9:702. doi:10.3390/ani9090702.
- 804 48. Pilley JW, Reid AK. Border collie comprehends object names as verbal referents.
805 *Behav Process.* 2011; 86:184-195.
- 806 49. Fugazza C, Miklosi A. Depths and limits of spontaneous categorization in a family
807 dog. *Sci Rep.* 2020; 10:3082. doi: 10.1038/s41598-020-59965-6.
- 808 50. Pilley JW. Border collie comprehends sentences containing a prepositional object, verb,
809 and direct object. *Learn Motiv.* 2013; 44:229-240.
- 810 51. Hare B, Woods V. *The genius of dogs – How dogs are smarter than you think.* New
811 York: Dutton; 2013.
- 812 52. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M,
813 Vijayakumar P, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-
814 CoV-2. *N Engl J Med.* 2020; 383:1283-1286.

- 815 53. Silva J, Lucas C, Sundaram M, Israelow B, Wong P, Klein J, et al. Saliva viral load is a
816 dynamic unifying correlate of COVID-19 severity and mortality. medRxiv [Preprint].
817 2021 Jan 10:2021.01.04.21249236. doi: 10.1101/2021.01.04.21249236.
- 818 54. Klopfer PH. Animal cognition and the new anthropomorphism. *Int J Comp Psychol.*
819 2005; 18:202-206.
- 820 55. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. *N Engl*
821 *J Med.* 2016; 375:2369-2379.
- 822 56. Ojima M, Motooka D, Shimizu K, Gotoh K, Shintani A, Yoshiya K, et al. Metagenomic
823 analysis reveals dynamic changes of whole gut microbiota in the acute phase of
824 intensive care unit patients. *Dig Dis Sci.* 2016; 61:1628-34.
- 825 57. Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in gut
826 microbiota of patients with COVID-19 during time of hospitalization.
827 *Gastroenterology.* 2020; 159:944-955.e8. doi: 10.1053/j.gastro.2020.05.048.
- 828 58. Vesga O, Valencia AF, Mira A, Ossa F, Ocampo E, Agudelo M, et al. Dog savior:
829 immediate scent-detection of SARS-COV-2 by trained dogs. *BioRxiv [Preprint].* 2020
830 bioRxiv 2020.06.17.158105 [posted 2020 June 19; revised 2021 Apr 16; cited 2021 Apr
831 17]: [17 p]. Available
832 from: <https://www.biorxiv.org/content/10.1101/2020.06.17.158105v1.full>.
- 833 59. Jendry P, Schulz C, Twele F, Meller S, von Köckritz-Blickwede M, Osterhaus
834 ADME, et al. Scent dog identification of samples from COVID-19 patients - a pilot
835 study. *BMC Infect Dis.* 2020; 20:536. doi: 10.1186/s12879-020-05281-3.
- 836 60. Grandjean D, Sarkis R, Lecoq-Julien C, Benard A, Roger V, Levesque E, et al. (2020)
837 Can the detection dog alert on COVID-19 positive persons by sniffing axillary sweat

- 838 samples? A proof-of-concept study. PLoS ONE. 2020; 15:e0243122. doi:
839 10.1371/journal.pone.0243122.
- 840 61. Essler JL, Kane SA, Nolan P, Akaho EH, Berna AZ, DeAngelo A, et al. Discrimination
841 of SARS-CoV-2 infected patient samples by detection dogs: A proof of concept study.
842 PLoS One. 2021; 16:e0250158. doi: 10.1371/journal.pone.0250158.
- 843 62. Jones RT, Guest C, Lindsay SW, Kleinschmidt I, Bradley J, Dewhirst S, et al. Could
844 bio-detection dogs be used to limit the spread of COVID-19 by travellers? Journal of
845 Travel Medicine 2020; 27:taaa131. doi: 10.1093/jtm/taaa131
- 846 63. Dickey T, Junqueira H. Toward the use of medical scent detection dogs for COVID-19
847 screening. J Osteopath Med. 2021; 121: 141–148.
- 848 64. Duffy DL, Hsub Y, Serpell JA. Breed differences in canine aggression. Appl Anim
849 Behav Sci. 2008; 114:441-460.
- 850 65. Mikkola S, Salonen M, Puurunen J, Hakanen E, Sulkama S, Araujo C, et al. Aggressive
851 behaviour is affected by demographic, environmental and behavioural factors in
852 purebred dogs. Sci Rep. 2021; 11:9433. doi: 10.1038/s41598-021-88793-5.
- 853 66. Horton R. Offline: The case for No-COVID. Lancet. 2021; 397:359. doi:
854 10.1016/S0140-6736(21)00186-0.

855

856

857 **Conflicts of Interest**

858 The authors declare no conflict of interest.

859

860 **Authors Contributions**

861 OV came up with the idea, obtained the funding, designed and supervised the training and
862 the experimental process, took medical care of the patients with COVID-19 who
863 participated in the study, and wrote the manuscript.
864 MA coordinated the experimental process; obtained, processed, and made available SARS-
865 CoV-2 for experimentation; and took medical care of the patients with COVID-19 who
866 participated in the study.
867 AFV directed the training process and supervised the dog experiments in the field.
868 AM, FO and EO trained the dogs and participated in all the experiments with them.
869 AFV, AM and FO obtained and processed the saliva specimens from 100 healthy
870 volunteers.
871 KC, LP, AC and YA performed the molecular biology work.
872 YA directed the logistics and organization of the experimental process with COVID-19 and
873 control patients within *Hospital Universitario San Vicente Fundación*.
874 JPH-O and JO supervised the virology and molecular biology work, wrote the manuscript,
875 and made invaluable comments to improve its quality.
876

877 **Ethical Statement: animal usage and human samples**

878 The study protocol was approved by the Ethical Committee for Human Research of
879 HUSVF and the Animal Research Ethics Committee of Colina-K9. All human subjects read
880 and signed their informed consent. We did not subject our dogs to any kind of pressure for
881 training. We did not starve the dogs and did not need to make them fanatics for food, toys,
882 games, or anything else. Since it is impossible to force a dog to do scent-work, our methods
883 are exclusively positive, rewarding every correct response, and being indifferent to any
884 mistake.
885
886